重庆莱美药业股份有限公司2025年度报告详解

重庆莱美药业股份有限公司（股票代码：300006）于2026年3月18日发布了2025年度报告摘要，内容包含公司经营状况、财务数据、重大事项及未来发展方向。以下为主要内容及对投资者有影响的关键事项详细解读：

一、公司经营及业绩要点

• 主营业务：公司专注于医药制造，产品涵盖化学药物、特色专科类（抗肿瘤药、消化系统药、肠外营养药）、抗感染类等。拳头产品“纳米炭混悬注射液（卡纳琳）”已连续多年获行业荣誉，并入选重庆市首批未来产业标志性产品。该产品具有淋巴示踪及靶向治疗功能，市场领先。
• 其他主力产品：包括盐酸克林霉素注射液、艾司奥美拉唑钠、艾司奥美拉唑镁肠溶胶囊、头孢泊肟酯干混悬剂、注射用盐酸纳洛酮、注射用磷酸氟达拉滨等。
• 研发、生产、采购、销售模式：
  • 研发层面，公司积极引进优质项目及创新技术，通过战略合作、股权投资等方式丰富产品管线。持续推进自主创新和仿制药业务。
  • 生产方面严格遵循法规，确保药品质量和安全。
  • 采购流程严密，全过程管理。
  • 销售结构优化，加强终端市场掌控力，提升重点产品市场占有率。
• 业绩驱动：2025年公司营业收入为7.76亿元，同比下降2.5%；归属于上市公司股东的净利润为-1.35亿元，亏损扩大。主要原因是部分品种销量及价格下降，同时公司持续研发投入增加，计提无形资产减值准备等，影响经营利润。

二、财务及股东结构变化

• 资产及净资产：总资产25.75亿元，同比减少9.84%；归属于上市公司股东的净资产17.56亿元，同比下降6.37%。
• 现金流：经营活动现金流净额为2603万元，同比降幅高达85.93%，显示公司现金流压力显著。
• 股东结构：控股股东为广西梧州中恒集团股份有限公司（持股23.43%），其次为邱宇（持股10.48%，全部股份被冻结）。公司间接控股股东发生重大变动，广投集团将控股权转让至广投金控，中恒集团仍为直接控股股东，广西国资委仍为实际控制人，此项变动已完成登记，可能影响公司治理及未来战略。

三、重大事项及潜在价格敏感信息

• 重要股东变动：持股5%以上股东邱宇因债务逾期，其持股遭国海证券通过集中竞价方式处置，全部股份被冻结。此举可能引发市场对公司股权稳定性的关注。
• 投资新项目：公司以自有资金4000万元参与投资广东东纳协同产业投资合伙企业，涉及医疗创新产业，显示公司多元化布局。
• 新药及医疗器械注册进展：
  • 多款新药获国家药品监督管理局批准，包括注射用尼可地尔、克林霉素磷酸酯注射液、盐酸纳洛酮注射液、阿奇霉素颗粒、注射用吗替麦考酚酯、尼可地尔片、酮咯酸氨丁三醇注射液、注射用氨曲南。
  • 控股子公司四川瀛瑞自主研发“纳米炭铁混悬注射液”获临床试验批准，将用于实体瘤患者联合放疗，布局创新肿瘤治疗领域。
  • 控股子公司海南医疗器械获两项医疗器械注册证。
  • 部分仿制药如玛巴洛沙韦片获得伦理批件，有望加快上市进程。
• 利润分配政策：公司2025年度不派发现金红利、不送红股、不以公积金转增股本，且母公司未分配利润为-4.8亿元，显示公司资金压力较大。

四、投资者关注点

• 公司持续亏损，近三年净利润持续为负，且亏损幅度逐年扩大，需警惕未来盈利能力。
• 新药获批及重大股权变动均属价格敏感事项，有可能影响公司估值及市场预期。
• 大股东股份被冻结及被动减持，可能影响市场对公司稳定性的信心。
• 公司积极布局新药与医疗器械领域，若相关产品上市进展顺利，将成为业绩新的增长点。

免责声明

本文基于重庆莱美药业2025年度报告摘要编写，仅供投资者参考，不构成投资建议。投资者应结合自身风险偏好及市场情况，谨慎决策。

Chongqing Lummy Pharmaceutical 2025 Annual Report Detailed Analysis (English)

Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE: 300006) released its 2025 annual summary on March 18, 2026. The report covers business operations, financial data, major events, and future development direction. Key details for investors are summarized below:

1. Business and Performance Highlights

• Main Business: The company specializes in pharmaceutical manufacturing, with products including chemical drugs, specialty drugs (anti-tumor, digestive system, parenteral nutrition), and anti-infective drugs. The flagship product, “Nano Carbon Suspension Injection (Kanalin),” has won multiple industry awards and was listed as a “Future Industry Landmark Product” by Chongqing. It is used for lymphatic tracing and targeted therapy.
• Other Key Products: Clindamycin hydrochloride injection, Esomeprazole sodium injection, Esomeprazole magnesium enteric capsules, Cefpodoxime dry suspension, Naloxone hydrochloride injection, Fludarabine phosphate injection, among others.
• R&D, Production, Procurement, Sales Model:
  • R&D: The company actively introduces quality projects and technologies through strategic cooperation and equity investment, while continuing self-innovation and generic drug development.
  • Production: Strict compliance with regulatory requirements ensures drug quality and safety.
  • Procurement: Rigorous full-process management.
  • Sales: Optimized structure, strengthened terminal market control, increased market share of key products.
• Performance Drivers: In 2025, revenue was RMB 776 million, down 2.5% YoY; net loss attributable to shareholders was RMB -135 million, with losses widening, mainly due to declining sales and prices of certain products, increased R&D spending, and asset impairment provisions.

2. Financial and Shareholder Structure Changes

• Assets and Equity: Total assets RMB 2.57 billion, down 9.84%; shareholders’ equity RMB 1.76 billion, down 6.37%.
• Cash Flow: Net cash flows from operations RMB 26 million, down 85.93%, indicating significant cash flow pressure.
• Shareholding Structure: Controlling shareholder is Guangxi Wuzhou Zhongheng Group (23.43%); second largest shareholder Qiu Yu (10.48%, all shares frozen). Significant indirect control change completed: Guangxi GT Capital became indirect controlling shareholder; Zhongheng Group remains direct controlling shareholder; Guangxi SASAC remains ultimate controller. This may impact future governance and strategy.

3. Major Events & Potential Price-sensitive Information

• Key Shareholder Changes: Qiu Yu (over 5%) had all shares frozen and disposed of via market due to overdue debts with Guohai Securities. May affect perceptions of shareholding stability.
• New Project Investment: Company invested RMB 40 million in Guangdong Dongna Synergy Industrial Investment Partnership, demonstrating diversification into medical innovation.
• Drug Approvals and Medical Device Progress:
  • Multiple new drugs approved, including Nicorandil injection, Clindamycin phosphate injection, Naloxone hydrochloride injection, Azithromycin granules, Mycophenolate mofetil injection, Nicorandil tablet, Ketorolac tromethamine injection, Aztreonam injection.
  • Sichuan subsidiary’s “Nano Carbon Iron Suspension Injection” approved for clinical trials in solid tumor patients, expanding innovative oncology pipeline.
  • Hainan subsidiary obtained two medical device registration certificates.
  • Generic drug “Baloxavir marboxil tablet” passed ethical review, potentially accelerating launch timeline.
• Dividend Policy: No cash dividend, bonus shares or equity transfer for 2025 due to accumulated losses (-RMB 480 million), indicating financial strain.

4. Investor Focus

• Continued losses over three years, with widening net loss, raising concerns about future profitability.
• Major drug approvals and shareholding changes are price-sensitive and may impact valuation and market expectations.
• Large shareholder’s frozen and disposed shares may affect confidence in stability.
• Active expansion in new drug and medical device fields—successful launches could drive future performance.

Disclaimer

This article is based on Chongqing Lummy Pharmaceutical’s 2025 annual summary and is for reference only. It does not constitute investment advice. Investors should make decisions based on their own risk tolerance and market conditions.

View 莱美药业 Historical chart here